, a core medical imaging lab focused on accelerating the crucial clinical trial process for pharmaceutical and medical device manufacturers, has officially launched.
Pharmaceutical and medical device manufacturers understand that medical imaging plays an integral part in the clinical trial process by helping to validate which drugs and devices are demonstrating efficacy. By identifying what is referred to as “imaging endpoints” (the overall outcome the clinical trial protocol is designed to evaluate), these companies, with the support of a core imaging lab, can effectively obtain results and determine if those endpoints are met. Imaging Endpoints provides the efficacy support needed to garner FDA approval to introduce new products to the market with the intent of improving patient outcomes.
Imaging Endpoints sets out to expedite the clinical trial process and serves as a central hub for collection, processing, quality review and standardized radiologic analysis of medical images. Additionally, Imaging Endpoint radiologists serve as blind readers and provide medical image interpretation, a fundamental component of the core imaging lab business for clinical trial sponsors.
Imaging Endpoints specializes in oncologic, cardiovascular, neurological and musculoskeletal trials. Imaging Endpoints is comprised of a group of board-certified, fellowship-trained radiologists and project managers.
Imaging Endpoints’ project managers have experience in clinical trials within pharmaceutical and medical device companies, and its parent company has functioned as a clinical imaging site in numerous trials.
Ronald Korn, MD, PhD, serves as Imaging Endpoints’ medical director.